News headlines about Vitae Pharmaceuticals (NASDAQ:VTAE) have been trending positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vitae Pharmaceuticals earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4093141291603 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/03/positive-news-coverage-somewhat-unlikely-to-affect-vitae-pharmaceuticals-vtae-share-price.html.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Insider Buying and Selling by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Receive News & Stock Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.